Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678000 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
A Phase 2 study of Chronic Kidney Disease (CKD), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 12
- Study locations
NCT02678000 is a Phase 2 study of Chronic Kidney Disease (CKD) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 84 participants, below the 2,258-participant average among 8 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 6 states.
The verdict
NCT02678000, a Phase 2 study of Chronic Kidney Disease (CKD), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 12
- Study locations
Study Summary
This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LHW090
Study Locations (12)
Other
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Elsterwerda
- Novartis Investigative Site - Erlangen
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Mannheim
Florida
- Novartis Investigative Site - Miami Lakes
- Novartis Investigative Site - Orlando
Minnesota
- Novartis Investigative Site - Minneapolis
- Novartis Investigative Site - Saint Paul
California
- Novartis Investigative Site - Anaheim
Colorado
- Novartis Investigative Site - Lakewood
Louisiana
- Novartis Investigative Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2018-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02678000
The ClinicalTrials.gov registry entry for NCT02678000 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,258-participant average among 8 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (96% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease (CKD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02678000 reports 12 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02678000 about?
NCT02678000 is a clinical study titled "Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function". This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.
What is the current status of trial NCT02678000?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-03-10. Estimated completion is 2018-10-11.
What conditions does trial NCT02678000 study?
This clinical trial studies the following conditions: Chronic Kidney Disease (CKD).
What interventions are being tested in trial NCT02678000?
The interventions under investigation include: Placebo (DRUG), LHW090 (DRUG).
Who is sponsoring clinical trial NCT02678000?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02678000 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease (CKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
RECRUITING
-
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
RECRUITING · Phase 1
-
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
RECRUITING · NA
-
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
RECRUITING
-
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.